N
Google TrendSOCIAL SECURITY 2027 COLA ANNOUNCEMENT (500+) — When will 2027’s Social Security COLA be announced?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:social security 2027 cola announcement500+benfica vs vitória sc200+energy ceasefire200+elliot anderson200+r.c.d. mallorca - u. d. las palmas200+quinyon mitchell2000+tornado north carolina1000+sean young500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Longer-Term Data Continue" (30 stories)

Top Headline Story

Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
Lead StoryOncLivegeneral
Aug 14

Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNcGtxbzg0M1pSRzhBNUZzdmt5aTM0MUlxbVcyMXc5azZldnJBeU9ZQnFENDR2WTktZFB5WXRQZUhWMnFsZGZrMTZkRzN6Y0xGQWtuX3g2emJhYUNsakMxa0Z0c0Y3dmJMZVVrZjFGd0l3eHJVSmRadXNtcUNMYlhjZWtFMzVBSGt6LUdCNEVBeGpGS0I1M0R2c0RrZ3U5M19ac2Z2Xzd6OG1uYXM2YThjUWxoV2V3UVBES2hwZm5jdw?oc=5" target="_blank">Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+20m ago

social security 2027 cola announcement

When will 2027’s Social Security COLA be announced?

Filter stories
200+30m ago

benfica vs vitória sc

Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável

Filter stories
200+30m ago

energy ceasefire

Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’

Filter stories
200+30m ago

elliot anderson

James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton

Filter stories

Search Results for "Longer-Term Data Continue"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
Yahoo Financegeneral

AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOTmNvNVVuMzZmTWNmRjJLNnRZNkRyZ2hldW5MLU5NOWNCbXRHa2hkY0Q4NTE5YjVtcm1SNXFLaDRfQ3JVc0V6TWdpU054Y2NjWEU3NkhSZXpObTc5TWMtaGxiTTJLR2JucjNfcVR0ajQxY3FpWmlvbTQzVVBFSmVXQ3JOQlQtVGRoMDU2ZHRrOXZ6VlpSdTdQZg?oc=5" target="_blank">AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain
AJMCtech

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQOTA1b1NRb1VsNE8xbGFOSFdIRVlSUFBuSEdaRWgtRDd2ckFXSUZNM054enhidGNFbFA5Ujl5ZmpybkVkYkhTbklyR0xlbXBXa1gtdnZENmR2VDlkQVBlYmJnZTB4azRlb1lRZFFLNUdDVE5BeHNPZ0duTjRRTlBMSWpVMXNQamNsd2JEenJGRi1QVnJMQ09CMGh1aHBKMkVVVmhv?oc=5" target="_blank">JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Long-term Data Show Continued Efficacy and Safety of Sparsentan in FSGS
DocWireNewsgeneral

Long-term Data Show Continued Efficacy and Safety of Sparsentan in FSGS

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPQU82TTlwa2w4ZXVlOVRyM1BWMmIyZUZHWTFxeE80aTlZeEZ0aXFRcXViQ0p2ZVhrc2xsUjZXb1hWTF9rVEhVM0x3LUlPZ19mYWx6MDZoU3NVMWhnN0JvWl9OeXA5X29NczdzaEpwNHNjWkkwUjQtZUhQQlY1SXFfYlExM0ZIanVJSjhmNks1WXB6aWd3M1B2T1BTWG96QkNFNGN2aGIzaw?oc=5" target="_blank">Long-term Data Show Continued Efficacy and Safety of Sparsentan in FSGS</a>  <font color="#6f6f6f">DocWireNews</font>

Read Full StoryMore like this
Questions over water use continue as Google data center debate grows in Botetourt County
WSETtech

Questions over water use continue as Google data center debate grows in Botetourt County

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNTEtmM2NfajVqYTFDM09BRmFDREVBVFJDUnJCSURxQkNpUGoySU9KNlVGUlBCaVUxRFltaVFLZU5DdnNJamFVakNscWpsZ3Vla0JuY1BKNXdTc0VDcVRjZWg3NE9wTFBiS28zUUhTa3Vac1JvZ2xVRFFxWE5EaGxaMGp6RmQxS1NwZi1FaXBrRXpWdzNBRXV0eUltcV81LW1DQU82VzFZbkZFTHpXN3NYY0ctVUxoNURhN1loaXZHNk1vQ24zSjNvVExJYlRaeThHOGpNUWZETG1wWjBUYlA4YWNaZmQxODhub0huOFVB?oc=5" target="_blank">Questions over water use continue as Google data center debate grows in Botetourt County</a>  <font color="#6f6f6f">WSET</font>

Read Full StoryMore like this
GTX-102 data show continued developmental gains in Angelman
Angelman Syndrome Newstech

GTX-102 data show continued developmental gains in Angelman

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOajZtdWRPVlZGUnNGVjJqLVRqbWlFTmxNaGh2N0NBN3FXLUJJODdOVEJWQzhxZmlBZ0ViekNDLUwwSWsxdk4yTE5hVXd0T1VoUWlDelVqTG9KMzNzNXRWMzluUU05TjFUUTUyU3ZWdm1YcGRidEdaaENQX2RoYnhwTE9xX1hSX20zSFAxWWNDeU5Hd2FSNkxST0Yzaw?oc=5" target="_blank">GTX-102 data show continued developmental gains in Angelman</a>  <font color="#6f6f6f">Angelman Syndrome News</font>

Read Full StoryMore like this
Uranium Price Update: Q1 2026 in Review
Investing News Networkgeneral

Uranium Price Update: Q1 2026 in Review

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5haUhWS1B1WlUwSFFpNmsxT3R4Y0ZjdVNTWE5hN254RHNtZS14eXRvM3VRRVQ2QmxYVWZqbjZDUDFVaVlJS0dZWWtLcElPS1FkemttSWh3?oc=5" target="_blank">Uranium Price Update: Q1 2026 in Review</a>  <font color="#6f6f6f">Investing News Network</font>

Read Full StoryMore like this
Residents raise concerns about data centers' environmental impact, long-term resource use
KUTVtech

Residents raise concerns about data centers' environmental impact, long-term resource use

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNbDdRaEFlOGFzc3AwRUYxWnFGZVk0UW5PTllmUkNQTzZoZkdjVnJQTGZLcUtDY05MbGt1b21FRWZNRTI4SlhQbXYzWlhPMHRPY3I3NWFTcTdzWUlYR3J5YkJwb3RmdG9FWEFIelJVQ0Rfc3NSN1ZVMUl3OGZWTDZWVUEzTm85RFBoQjctTG9iRFlTZW92ckRwY3NibktGeGFRZ1JyOEZuenRZSHVsUWI1YWpxd2t5Zw?oc=5" target="_blank">Residents raise concerns about data centers' environmental impact, long-term resource use</a>  <font color="#6f6f6f">KUTV</font>

Read Full StoryMore like this
PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI
TCTMD.comtech

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNa1FkU0dCS1RIakJKTW9CTHF0V0J1SjZmcXJpVnBqRGRyQ1J5U2RKMmRkSHJFOXUtN1I2ZHpONWtnZ21TeDRZYzNIZlI0WHZ1RmNxQ1c2OVlHZ3owVG4wTjJfcV9ER19hVkdocklJbmJrNFF3YlpSUVYzTEpoRXRtQWZndFRVVTlhNHFWUE9YbHdQUQ?oc=5" target="_blank">PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI</a>  <font color="#6f6f6f">TCTMD.com</font>

Read Full StoryMore like this
PJM’s Updated 20-Year Forecast Continues To See Significant Long-Term Load Growth
PJM Inside Linesgeneral

PJM’s Updated 20-Year Forecast Continues To See Significant Long-Term Load Growth

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNOHFvd0l6R1BNMHo5dENzWlltc0lJcmRLZTd0ZUlxRVd6SExGam5FN3hUYWxMZWtFcFFKTWh3eC15RWtiM1hiNk9hZ0dFSVN1bWlCUy13OS12OWlWWFFyM21saTlscUVDZDg5REt4UFRxRmxwWEp1MkU2VENxbHE1cWl6RUMxTW9keF9tR09saE9hS185VkRFajJzX1R3OTBIVmlGQnpQdUR4WW15THc?oc=5" target="_blank">PJM’s Updated 20-Year Forecast Continues To See Significant Long-Term Load Growth</a>  <font color="#6f6f6f">PJM Inside Lines</font>

Read Full StoryMore like this
Ultragenyx Announces Positive Longer-Term Data
GlobeNewswireworld

Ultragenyx Announces Positive Longer-Term Data

<a href="https://news.google.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?oc=5" target="_blank">Ultragenyx Announces Positive Longer-Term Data</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
Biogentech

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQSDFnZy1YS2JZUEhwWHpWOHRyUms2aUExbDFwS3AyMFQtcXNBZkd0V3FzYkhGNmhVSnNxc3VzbjlDU1Jjc3lKejdZTzRVajBfTmhRVERnaEE1dWdFUUZsX3hZMVhZVXhLQVA0eUhCSWM3RENoc2FSUXBoeXRWM09VWUtKMElTR0R3ZHU3RWtKeEVBeHFGd2k1ek4zTGgxTEtDVExDRkpEV1BoYTktUFpBNTNlMlp6cnVMTzFqVnN0SE93bzRDRHQ4?oc=5" target="_blank">Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL
OncLivetech

SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQZElFeThEaXhRMmkwTFBCRGlnaHlnUlJqOWFaT3JqYUVFRUFWWjA4QzZzVHl2R0VmeW5CeGl4a0NkbHZNVG1hRFM0SnFrOW9LVy1EOUhGc0p2Q08wdTRxTnNzbnBtc3dmSGNKbjhVNHplR0dPVHBiR2tsU2h6WDZlenFTbWgzVzh4Y3pJeHBXcWJZbVJHWWNfeDlxSWV6blJOLXFsbXJpQXlYNV9CcmhXZA?oc=5" target="_blank">SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
PR Newswireworld

Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology

<a href="https://news.google.com/rss/articles/CBMi4wJBVV95cUxOS3lPYV9SZFBTZHdrWldhcktlUUg0b180VlhrZmxCWXZibGFNQlRXYmpBUi1CSldjVzJ6R3M1bmJYMFBKQzd3WjBlNDNOdFYtSjRxTDZHOGNET1RhT1c3a0FrNDZmOVpBQkhrQmJHdkRWLVNHOUUta0hUc29vN0tYLUNVT3l5b05qSHRHVFg5bzRUdW91ZDhrS0lQVjVBUWNVam5JeDZnSVBoXzRLM2syM3JMQTVEeWhJWXFlZTFGY0lZakNPZHBSdVY4TlhmMW9jS1lwd3NBVElMY0Q5TDNsb2hPOWdxY0xKaFZfUkRLbFZlQWpmTmVvRmZMbVhmNXczVVdNTk9rcl95Qm9HTnNvQ3B0eEwyZ2NiRUFNdVZldkFSX2REak03bUNhSkZJVHVTUERsdDZYSldUT2d6VDFOa05vMmZFbzRFcjFtUF9YZXoxRlZaSXBjaUpfdk5aa2NhUzRv?oc=5" target="_blank">Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
New Long-Term Data Suggest Continued Blarcamesine Efficacy in Alzheimer Disease Up to 4 Years
Patient Care Onlinegeneral

New Long-Term Data Suggest Continued Blarcamesine Efficacy in Alzheimer Disease Up to 4 Years

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQQlhMLURFLW94SjVGNDVaOHVHQjBIQ1NheENkNjVHM3dRU292UTJ0elc3aWpiemhXbUl6MF9QdUZKeHVBMHdGR3B3Q1JkTkl6c2JwQVNrMGNhclRwemRxVWNiczFUbFNKSUV4X3UwU3ZrbDlNOTcxQXhZX1d6V3AyMkFPcDMxRDBIWHRCcTNJdUQxclZtZWNNYndyWjgxemVvcVh2Yms4MW1GNllMSGRPV2FHamwwaDNfbmRieFhzMExNelpKTVpiem1lbko?oc=5" target="_blank">New Long-Term Data Suggest Continued Blarcamesine Efficacy in Alzheimer Disease Up to 4 Years</a>  <font color="#6f6f6f">Patient Care Online</font>

Read Full StoryMore like this
Foralumab nasal spray continues to show long-term safety in SPMS: Data
Multiple Sclerosis News Todayscience

Foralumab nasal spray continues to show long-term safety in SPMS: Data

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNcnYtY1V0aml2X3llN3p2ZzJxeThBeFpKN2k5aWZyX2xJdnZGc3hKV3NXbDhNUXktOGczN3k1cEhldzVyNW5QemFIZDUwTWVZdU9kdGxBTXBGNXFBWmlFb0lvUUNxSWItbVo0YWtEZFNkcGFqU1gyWHp0SG40NXRzdXJZTFh0ZHV4cl9MQXdCM0ZyR0VKQ09jYldZTXlUM010UW83azZSNHl4MWFaSmlVaWJCRVQ?oc=5" target="_blank">Foralumab nasal spray continues to show long-term safety in SPMS: Data</a>  <font color="#6f6f6f">Multiple Sclerosis News Today</font>

Read Full StoryMore like this
Long-Term Data Show Lasting Survival Benefit With Cemiplimab in Advanced NSCLC
Oncology News Centralgeneral

Long-Term Data Show Lasting Survival Benefit With Cemiplimab in Advanced NSCLC

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOLUt3X0dCdVZyTFdtREh6d01PTFJOREhXM25nc1lLT04yQzZsS0pyOFU3alRmMHp2RDV2aThadUR4TEZ2bnItbXNNcW52a3o0QUEzMEhxcUZyTVBTSVRzMlNCcFI3Q0w4eko5aXZaVWpTeG5FRUlVbFdZTi1xck8yNzdvanJVQUhhWTRvdXFsOTluMHVobjN1TGo0T3lMeDF1cU0yNk9MYkY0S2RzVmZweVpfeTZtSnhlRl95Mg?oc=5" target="_blank">Long-Term Data Show Lasting Survival Benefit With Cemiplimab in Advanced NSCLC</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Intellia Therapeuticsworld

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPaENGUGRQbGVQVkxzSDJXbF9sdEkzWVNpOW5XcVZMOEU1RG9MX29ReVBMMmFnRlpQdnV5dmhHbml1UkM4SkIxWTVqTjA4bHZyam92eW5STXdLOFBzQzB0end3bzJpYlFVR29fTTBCRXlfbEp6Zm1DZ3NxUjVMb3NVUml4Rl81WHFrVWgyQTRQcl9jV3kyNFYtRUpsbldod0J5QjRSWEZ2Mmgycm0xQWRONGlwVEhiRVBMWlJ6M01B?oc=5" target="_blank">Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy</a>  <font color="#6f6f6f">Intellia Therapeutics</font>

Read Full StoryMore like this
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Biogenworld

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPV2Y3cmhFZTcxVVdPYlMzRFRCMmhwM25mU0lGbXlDMUgtRm1QdU1KU0JGZHZzR1pFVVhiVk1JMndSV0tHY1BGcXd0RUJUUHVMc0JpYzZkZGZLT05fZWFzNEdRLTRmYWlVS0UzempaZjJxNzd3bS1xUnVZb1ZtUHE4NE4wem1tdzJZZ3dieS1oZTBybzNreTRPYWdaMS1hYnU1X0VrU3lUWXJtS1FtcnNoOXdqQ0JRZWlqVmI5VXBfVEFTeXh4R2NJ?oc=5" target="_blank">Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
Long-Term KEYNOTE-426 Data Continue to Support Frontline Pembrolizumab Plus Axitinib as SOC for Advanced ccRCC
OncLivegeneral

Long-Term KEYNOTE-426 Data Continue to Support Frontline Pembrolizumab Plus Axitinib as SOC for Advanced ccRCC

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOdm5XQW52YmR0blAySHhiNHMyeDZ2LVNxOVNUTlNjUmNGUGhLb09QZUlERTBORjBtajdCSHBURXlTUFNYTnpTb0dZTWFzWklXOTBCdy0zQ2VJNU9tRy1VTjJjaDNzazRPSjJRYVRxajFQckktVUtlV3ZZMVBiaGswcnpKV2xTa1EyNlUtWV9RYVJnbmRTSnFfVnVTb3FoSlZQY19xQ3R2OFdGb3p4eGYzY09Nd3ZDdGVVcVJ3NWNtVEloTURKUmo4MEVQWVFDczB3MzhvWUln?oc=5" target="_blank">Long-Term KEYNOTE-426 Data Continue to Support Frontline Pembrolizumab Plus Axitinib as SOC for Advanced ccRCC</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Eisai Co., Ltd.tech

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5aUjVGQ1dxTlJLdDVjSFk5U05Nc3Y1YmNIV09SZjdOaWpKOWdCM0F6cGk4RTR4TU1LbEdMbm1idDFuZWpaU1d3UndPc2JheTR2cTEwQUtrQy1QdHM?oc=5" target="_blank">Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC</a>  <font color="#6f6f6f">Eisai Co., Ltd.</font>

Read Full StoryMore like this
Alzheimer's Benefits Continue With Donanemab for 3 Years, Long-Term Data Show
MedPage Todaygeneral

Alzheimer's Benefits Continue With Donanemab for 3 Years, Long-Term Data Show

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5rUnIxckRjam9TajhiTkh4TTZEWnZyNlotTUpMcm5yTmY2M1RuVnB5MGxuWmdEdm9DZnkwTGZQTWpwbWpuZnA0VWtiWUhOY2R5Yl9MamxIdnlwd01nSXh3RTMwUG5zRjA?oc=5" target="_blank">Alzheimer's Benefits Continue With Donanemab for 3 Years, Long-Term Data Show</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade
GSK UStech

New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQQkUyaGRtZUNiRUt4bkpGNkRrdjFURDdtOGRaQ0kwY21yaE5NUlFzLWdxSklBODhkQjlhVlJJdl94NjZlLWxYVmFFR09hZFNoc3hyRV85RjFyN0diNjdsT1pFaXh6c1lMaUwyR0szTng1aHVlMUlON1pQM0hvVVB6MGQ2NUdxbXk1UGV3NDdzd0hXZEVNU0Q0NkJZdnEwaTBCR3F2NTl6T2tjTmhUaTljU3BLV1RTRHlHMFlSR3h4cDdMMzlNZG5mMS1EdFlqUQ?oc=5" target="_blank">New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade</a>  <font color="#6f6f6f">GSK US</font>

Read Full StoryMore like this
OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer
The ASCO Postgeneral

OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNVlQ4T3B4elBlcmF1ekN5V1NNd1NvQjA2YmZBdlJmYXJuOHFHemFuLTAwZ21hOFdySnNndzV5TWd2MVFHNUNxZkxQMTBEbW91TFZNWTY1cXpMLTJxeXJNLUhRbmFjbkE2NzVNR1RiOEl6UFAtbE1HbTFNYzgtMnI5N0NId09XRENJTlFLR1F2bXI5Z193YXAtcXYzSHZ3eDdZYU9EcGROdnRBYlM2dWVwU0RPMGsyZjB1MjhwcVhaMEFrLUlWWW5BUkNUdkR2TWZXVE1Reg?oc=5" target="_blank">OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Energy Bills: Short-term relief, longer-term challenges
Bank of America Institutepolitics

Energy Bills: Short-term relief, longer-term challenges

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE5MSzNhWkFQMVVKeFdibjVsbHBHM1lHLU9VbC1VMEoyZ0o5OGZNMTlsOXN4SExpdzQzaTRJTm5JekZ3di1IbEVaQmkxYWwwQjFDRXl6MmY0TjF0N1VnVDZZS0NxTzViVXdubmlybGhQNnI5dHE1ajNCcEJWWQ?oc=5" target="_blank">Energy Bills: Short-term relief, longer-term challenges</a>  <font color="#6f6f6f">Bank of America Institute</font>

Read Full StoryMore like this
bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data
CGTLive®general

bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUXZ5Qk9RLXNmX1lVYzc4dldwUU5ERTdTdWN0OFhzYlBpZTVTS1o0TzZ6eFlNWUl2T3VmVUtEU3l1OGh1ZGxQbENwUFMtMGFtYU1zMVZjbXl4Z1JpM29hOXM3WThJazR3VU1ZZzMwU2hvWHNQdlBxeU1wVFA5U3F0Sk5FOGx4WWNXYlRlWGQ0SjhROU9ZOWkyR1lGQWl0N2dUZm1QZEFPRnZLaG9NdWEtblhUUVNWVHN4b3l5ZHhoRVJpOGJBZUdwMWdLOUh1QjRoLU1oVmg3ZFc?oc=5" target="_blank">bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data</a>  <font color="#6f6f6f">CGTLive®</font>

Read Full StoryMore like this
New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne
NeurologyLivegeneral

New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNWjBDdWs5dE5nR05LSTZoT2hCZHpXOVFDelg0NTZNTDM0cmZfUDI4M29hemt4RWVYZFVINmhCRXE4VzlzRTBPa25DZkZHZUNWWlhoUnQtbXdEU1FHWGZOVnA4MExzS3BoZERZTlV2aFZhOVVVb0RzQW0zWlVQRVJ1RVNfVlJCa1FMb0luTEJEelRRcWxLa29HY3M5bXB3VTg2Tlo3OTIzeVY3X3ZHb3dCMWY1bXVNNi1Hd1l4UjN2bGZadVd5T09j?oc=5" target="_blank">New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult H
BioSpacegeneral

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult H

<a href="https://news.google.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?oc=5" target="_blank">Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult H</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Turning the data center boom into long-term, local prosperity
Brookingsgeneral

Turning the data center boom into long-term, local prosperity

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOaER5QXA1ekxPWU9RMFB6b0FNMWJIN2pUUVpLeTBfTXQ2dzRXeGNhaU9vcGRVUFpaZDQtem1YRHpRRmdBVXpQdVdvLXZsR2JqbHFHVVhNc1VsQklaa2lwSzRnTC13SzRZMzVMS2ViaFBSZjlQSzlRa2FGVV82RFdXRWFFR3MtQ01iZ0lvaWJmWFI1alB3azc4b3BZeFk?oc=5" target="_blank">Turning the data center boom into long-term, local prosperity</a>  <font color="#6f6f6f">Brookings</font>

Read Full StoryMore like this
Researchers closely monitor bird flu outbreak in elephant seals at Año Nuevo State Park
Santa Cruz Sentinelgeneral

Researchers closely monitor bird flu outbreak in elephant seals at Año Nuevo State Park

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPRk5TRmxkT2pRUjRZRHZnUktuaHdCYVNRbWdjcU1kTDBBaEJaVDdtcHc2Z1I2M3V6QnQ0MTBrTWNtZ285SkMyOHBTZzFsNmlicHRoS3ptUThUOE1reHBkWWpPM09ELXlhZXhMZ1VBbDN6NnJtdk5IN245NDhFeFVpRkJTUVdnVEROamhvaEdoSlh0MERGdEFTQjJWWHNLOElCcU5ySElrRFBTeDVrRnhKUnJVXy1FUDkwZ2RPRGx4TUhTZC1TQkh6blRRQmVsQQ?oc=5" target="_blank">Researchers closely monitor bird flu outbreak in elephant seals at Año Nuevo State Park</a>  <font color="#6f6f6f">Santa Cruz Sentinel</font>

Read Full StoryMore like this
"Longer-Term Data Continue" — Live Google News Trends & Headlines